Skip to search formSkip to main contentSkip to account menu

MMI 166

Known as: MMI-166, MMI166 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Effects of a new matrix metalloproteinase inhibitor, MMI-166, in nude mouse xenografts of human pancreatic cancer
Objective To investigate of the MMI-166 on the expression of MMP-2,MMP-9 and the cell apoptosis of nude mouse xenografts of… 
2010
2010
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells
BackgroundThe constitutive overexpression of matrix metalloproteinases (MMPs) is frequently observed in malignant tumours. In… 
Review
2006
Review
2006
Author's response to reviews Title: Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells Authors:
Title: Predictors of extra care among magnesium sulphate treated eclamptic patients at Muhimbili National Hospital, Tanzania… 
2005
2005
Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer
Matrix metalloproteinases (MMP) are considered to be critically involved in tumor invasion and the metastasis of various cancers… 
2005
2005
P-037 New matrix metalloproteinase inhibitor agent, MMI-166, inhibitslymphogenous metastasis in an orthotopically implanted SCID mouse model of lung cancer
2004
2004
Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor
The anti-metastatic efficacy and safety of a newly-developed matrix metalloproteinase (MMP) inhibitor were examined. MMI-166, a N… 
2004
2004
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11
The anti-metastatic efficacy of MMI-166, which is a selective matrix metalloproteinase (MMP) inhibitor, in combination with CPT… 
2002
2002
Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
BACKGROUND MMI-166 is a selective matrix metalloproteinase (MMP) inhibitor. The purpose of this study was to evaluate the… 
2002
2002
Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck.
2001
2001
Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)